Recombinant adenoviruses for gene therapy in cancers

US RE39,078 Term ended

Term ended Apr 25, 2023 · From the USPTO record

Computed 20-year base term

Reissue of US 05,837,531, which was surrendered when this reissue was granted; its term and maintenance fees continue here.

Held by Aventis Pharma S.A.

Filed Nov 7, 1994 as application 09/654,223 · Granted Apr 25, 2006

Base term, 17 years from grant or 20 from filing, whichever is later

Today

17 years from grant or 20 from filing, whichever is later

Term ended Apr 25, 2023

1994 2026

Clock starts
Nov 7, 1994

Term ended
Apr 25, 2023

Granted
Apr 25, 2006

base term after the term ends Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know

None

Term adjustment

No prosecution delay on this record.

None

Terminal disclaimer

No disclaimer on this record.

0 of 3

Maintenance fees paid

Three maintenance fees fall due, at 3.5, 7.5 and 11.5 years from the original patent's grant, which is not on record here. This counts the ones the record shows paid.

How we calculated this date

One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.

Step	Input	Date after this step	Confidence
Base term, the 1995 transition rule	Granted Apr 25, 2006 + 17 years, or clock starts Nov 7, 1994 + 20 years, whichever is later; a parent in its chain could not be resolved (the next row)	Apr 25, 2023	High confidence
Continuity chain	A reissue: its term follows the original patent's, with the original's term adjustment; a parent in the chain could not be resolved	dated from this application's own claim	Low confidence
Patent term adjustment	No term adjustment record on a grant after 2005, so none is added	no change	Medium confidence
Terminal disclaimer cap	None on record	no cap applied	High confidence
Patent term extension	None on file	no change	High confidence
Fee events	The reissue's fees post to its original, whose fee record is not available (likely before 2001)	term ended	Medium confidence
Computed term end	The steps above, in order	Apr 25, 2023	From the USPTO record

Sources

Google Patents · The patent document at USPTO · Assignment records at USPTO

USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup

Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.

Not on this page: the patent's family, its recorded assignments and its citation count. USPTO's assignment records, linked above, list every recorded assignment.

Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Recombinant adenoviruses for gene therapy in cancers

Term ended Apr 25, 2023 · From the USPTO record

20-year base term ended Apr 25, 2023

How we calculated this date

Sources